Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

Moodys
Dow
Harvard Business School
Boehringer Ingelheim
Colorcon
Medtronic

Last Updated: November 16, 2019

DrugPatentWatch Database Preview

Drugs in Development Information for Amylamine

See Plans and Pricing

« Back to Dashboard

What is the drug development status for Amylamine?

Amylamine is an investigational drug.

There have been 18 clinical trials for Amylamine. The most recent clinical trial was a Phase 3 trial, which was initiated on April 18th 2019.

The most common disease conditions in clinical trials are Depressive Disorder, Depression, and Depressive Disorder, Major. The leading clinical trial sponsors are CoMentis, Yale University, and Targacept Inc.

There are two US patents protecting this investigational drug and twenty-seven international patents.

Recent Clinical Trials for Amylamine
TitleSponsorPhase
Pilot Study of Mecamylamine for Autonomic Dysreflexia ProphylaxisWayne State UniversityPhase 4
Exploratory Study to Assess the Efficacy and Safety of TC-5214 in the Treatment of Subjects With Palmar HyperhidrosisAtacama TherapeuticsPhase 2
The Nicotinic Cholinergic System and Cognitive AgingVanderbilt University Medical CenterPhase 1

See all Amylamine clinical trials

Clinical Trial Summary for Amylamine

Top disease conditions for Amylamine
Top clinical trial sponsors for Amylamine

See all Amylamine clinical trials

US Patents for Amylamine

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Amylamine   Start Trial Process for protecting bearings in steel mills and other metal processing mills Amoco Corporation (Chicago, IL)   Start Trial
Amylamine   Start Trial Polymers derived from unsaturated polyesters by addition of compounds with an amine function and their use as additives modifying the properties of petroleum middle distillates when cold Institut Francais du Petrole (Rueil-Malmaison, FR) Elf France (Corbevoie, FR)   Start Trial
Amylamine   Start Trial Preparation of organometallic amide compositions Lithium Corporation of America (Gastonia, NC)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Moodys
Medtronic
Johnson and Johnson
McKesson
Harvard Business School
Merck

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.